Dr. Herbert Nagasawa's RiboCeine Technology Now Fully Patented and Assigned to Max International
Max International is proud to officially announce that RiboCeine, the proprietary technology developed by Dr. Herbert Nagasawa and his team of scientific researchers, is now fully patented by the U.S. Patent Office. As per U.S. law, the patent has been granted to Dr. Nagasawa, who has assigned it to Max International. This means that the exclusive ownership and distribution rights for RiboCeine belong with Max International and our Associates. No other company or individual outside of Max International and our Associates may make, use, offer for sale, or sell products containing RiboCeine.
The acquisition of the patent demonstrates our commitment to developing real health breakthroughs backed by scientific research. The granting of this patent is a recognition of RiboCeine's innovative and unique design. When he learned about the granting of the patent, Co-CEO, Dave Bagley stated, "I have never seen a company more focused on scientific development than Max International. Through Dr. Nagasawa's efforts, the company has created an innovative line of supplements that help to promote a healthy lifestyle."
Max has put out a Press Release announcing the granting of the patent. To read a copy of the official release, see this post on the press release section of Max Solutions. To see the official patent, follow this link to the USPTO site.
* * * * * * * *
Independent Studies on Ribose-Cysteine
NOTE: The following links take you away from this page to 3rd party research sites.
1. Saltman A.E.D-Ribose-L-cysteine supplementation enhances wound healing in a rodent model. Am J Surg. 2015, 210, 153-158.
2. Kader, T.; Porteous C.M.; Williams M.A.J.A.; Gieseg, S.P.; McCormick, S.P.A. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. Atherosclerosis. 2014, 237, 725-733.
3. Jurkowska, H.; Uchacz, T.; Roberts, J.; Wrobel, M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation Amino Acids, 2011, 41, 131-139.
4. Heman-Ackah, S.E.; Juhn, S.K.; Huang, T.C.; Wiedmann, T.S. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation Otolaryngology-Head and Neck Surgery, 2010,143, 429-434.
5. Oz, H.S.; Chen, T.S.; Nagasawa, H., Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Translational Research, , 150(2), 122-129., 150(2), 122-129.
6. Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D. Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion. Basic Clin. Pharmacol. Toxicol., 2005, 96 (6), 487-94.
7. Waldron, C.A.; Vannais, D.B.; Ueno A.M. A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by Ascorbate and Ribs but not DMSO. Mutation Research. 2004, 551-255-265.
8. Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldron, C.A. The "Pro-drug" RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells.Radiation Research, 2003, 160, 579-583.
9. Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C. Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells. J. Med. Chem., , 44(16), 2661-2666., 44(16), 2661-2666.
10. Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D. Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity. Toxicologic Pathology, 2000, 28(5), 697-704.
11. Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B. Biodistribution of [35S] - Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies. J. Labelled Cpd. Radiopharm., 1999all.riboceine.study1.51
12. Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R. Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines. Chem. Res. Toxicol., 1998, 11, 1274-1282.
13. Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R. Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract). Biochem. Mol. Bio. Intl., 1997, 42, 1189-1197.
14. Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G. Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents. Radiation Research, 1995, 143, 203-213.
15. Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P. Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury. Dis. Colon Rectum, 1995, 38(7), 716-722.
16. Roberts, J.C.;Francetic, D.J.; Zera, R.T. Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents. AntiCancer Research, 1994, 14, 389-396.
17. Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P. Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid. Dis. Colon Rectum, 1993, 36(7), 681-687.
18. Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T. Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys). Pharmacology & Toxicology, 1992, 70, 281-285.
19. Roberts, J.C.; Francetic, D.J. Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine. Med. Chem. Res., 1991, 1, 213-219.
20. Roberts, J.C.; Francetic, D.J. Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys. Toxicology Letters, 1991, 59, 245-251.
21. Roberts, J.C.; Francetic, D.J.; Zera, R.T. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemotherapy and Pharmacology, 1991, 28, 166-170.
22. Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J. W. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(polyhydroxyalky)-and 2-(Polyacetoxyalky)-Thiazolidine-4(R)-Carboxylic Acids. . Med Chem., 1987, 30, 1891-1896.